InvestSMART

Cogstate Limited (ASX: CGS) - Announcements

Current share price for CGS : $2.930 0.2 (7.33%)+

ASX company news and announcements for Cogstate Limited (CGS) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Cogstate Limited (CGS) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Cogstate Limited (CGS), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Cogstate Limited (CGS)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$498 Contracts signed since 1 July 2014 hit $9 million 14 Aug 2014 9:20AM $0.290 $2.930 risen by 910.34%
$498 Cogstate signs $7.3 million sales contract 5 Aug 2014 9:28AM $0.280 $2.930 risen by 946.43%
$498 Appendix 4C - quarterly 22 Jul 2014 1:06PM $0.250 $2.930 risen by 1,072%
$498 Cogstate provides update on sales contracts 24 Jun 2014 9:22AM $0.300 $2.930 risen by 876.67%
$498 Cogstate signs first client to Precision Recruitment 12 Jun 2014 8:57AM $0.255 $2.930 risen by 1,049.02%
$498 Business update and guidance on FY14 results 6 Jun 2014 8:29AM $0.245 $2.930 risen by 1,095.92%
$498 Cogstate announces updated agreement with Merck Canada 2 Jun 2014 9:32AM $0.240 $2.930 risen by 1,120.83%
$498 Appendix 4C - quarterly 28 Apr 2014 12:00PM $0.315 $2.930 risen by 830.16%
$498 Cogstate technology chosen for major Phase III trial 24 Mar 2014 2:08PM $0.320 $2.930 risen by 815.63%
$498 Business Update - Significant growth in future revenue 18 Feb 2014 3:19PM $0.385 $2.930 risen by 661.04%
$498 Appendix 4D and Half-Year Financial Report 18 Feb 2014 3:18PM $0.385 $2.930 risen by 661.04%
$498 Cogstate Test to be used in large paediatric clinical trial 12 Feb 2014 10:26AM $0.370 $2.930 risen by 691.89%
$498 Appendix 4C - quarterly 28 Jan 2014 3:42PM $0.350 $2.930 risen by 737.14%
$498 Cogstate Awarded Tender 23 Dec 2013 9:59AM $0.360 $2.930 risen by 713.89%
$498 Rights Issue Offer Document 3 Dec 2013 10:32AM $0.390 $2.930 risen by 651.28%
$498 Fully Underwritten Non-Renounceable Rights Issue / Placement 19 Nov 2013 8:45AM $0.390 $2.930 risen by 651.28%
$498 Business Update and First Half Financial Guidance 19 Nov 2013 8:40AM $0.390 $2.930 risen by 651.28%
$498 Trading Halt 18 Nov 2013 9:48AM $0.450 $2.930 risen by 551.11%
$498 AGM Presentation slides 23 Oct 2013 3:27PM $0.530 $2.930 risen by 452.83%
$498 30 Sep 2013 Business Update and Appendix 4C 23 Oct 2013 3:27PM $0.530 $2.930 risen by 452.83%
$498 Merck releases new data on effectiveness of Cognigram 8 Oct 2013 10:35AM $0.475 $2.930 risen by 516.84%
$498 Growing recognition of Cogstate test as a cognitive tool 26 Sep 2013 9:24AM $0.460 $2.930 risen by 536.96%
$498 Appendix 4E and Preliminary Final Report 21 Aug 2013 9:38AM $0.420 $2.930 risen by 597.62%
$498 Quarterly Business Update and Cashflow - 30 June 2013 29 Jul 2013 2:30PM $0.320 $2.930 risen by 815.63%
$498 Appendix 4C - quarterly 29 Jul 2013 2:30PM $0.320 $2.930 risen by 815.63%

851 - 875 of 998 results

Page 35 of 40

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.